| Friday, 9th December, 2022 | |
| 08.30 – 08.45 | Welcome Jörg Fuchs |
| 08.45 – 10.00 | Session 1: New aspects of risk stratification New aspects and clinical relevance of the COG neuroblastoma risk stratification Meredith Irwin (Toronto) New Risk stratification of neuroblastoma – common strategies between SIOPEN and GPOH Prof. Angelika Eggert (Berlin) How relevant is pathology for diagnosis and the decision making process in neuroblastoma risk stratification Prof. Christian Vokuhl (Bonn) Molecular genetics of neuroblastoma and its clinical implications Matthias Fischer (Köln) Chair: Steven Warmann & Mike La Quaglia |
| 10.00 – 10.20 | Coffee Break |
| 10.20 – 11.50 | Session 2: Radiology and new aspects of diagnostic workup Imaging in Neuroblastoma: Recommendations of the SIOPEN Radiological Committee Irmina Sefic Pasic (Sarajevo) 18F-meta-fluorobenzylguanidine (18F-mFBG) in Neuroblastoma: Pros and Con Bart de Keizer (Utrecht) Combined metabolic and functional tumor volumes on PET/MRI in neuroblastoma Maryanna Chaika (Tübingen) Imaging of Gross Residual Disease After Surgery in Neuroblastoma: The COG Experience Stephan Voss (Boston) Early postoperative MRI after gross total resection: Tübingen experience and first results of a multicenter study Sebastian Gassenmaier (Tübingen) Chair: Stephan Voss & Jürgen F. Schäfer Introduction: Jürgen F. Schäfer |
| 11.50 – 12.50 | Lunch Break |
| 12.50 – 13.50 | Session 3: Radiation Therapy The envolving role of radiotherapy in neuroblastoma Beate Timmermann (Essen) The evolution of radiotherapy utilization in high risk neuroblastoma: Recent missteps and future directions Dr. John Lucas (Memphis) Results and complications of Radiotherapy in NB Mark Gaze (London) Chair: Rupert Handgretinger & Verena Paulsen |
| 13.50 – 14.15 | Coffee Break |
| 14.15 – 15.30 | Session 4: Immunotherapy / Car-T-cells Development of an Anti-GD2/B7-H3 Bispecific Antibody to Improve Tumor Targeting, Reduce Toxicity and Improve Efficacy for Neuroblastoma Paul Sondel (Madison) Targeting T cells and radioisotopes using bispecific antibodies Nai-Kong Cheung (New York) Haploidentical stem cell transplantation followed by anti-GD2 therapy in relapsed neuroblastoma Peter Lang (Tübingen) Long-term Infusion Holger Lode (Greifswald) Chair: Angelika Eggert & Maja Beck Popovic |
| 15.30 – 15.50 | Coffee Break |
| 15.50 – 17.05 | Session 5: Free talks Indications of the retroperitoneoscopy for neuroblastic supra renal tumors in children Nicoleta Panait (Marseille) Robotic assisted minimal invasive surgery for neuroblastic tumors – experiences from a tertiary pediatric surgical oncology center Kai Breuling (Munich) Contribution of 3D Imaging in the management of neuroblastoma with high surgical risk Nicoleta Panait (Marseille) Long-term outcomes of surgical treatment of pediatric neuroblastic tumors Hilmican Ulman (Izmir) Improving life quality by daily symptom assessment in neuroblastoma Roman Crazzolara (Innsbruck) Amplified N-Myc associated with non-malignant tumor: about one case Meriem Oumaima Beji (Monastir) Chair: Rochelle Bagatell & Chan Hon Chui |
| 18.30 | Congress Dinner |
| Saturday, 10th December, 2022 | |
| 09.00 – 09.20 | Key Note Lecture: History of Neuroblastoma Surgery Mike LaQuaglia, New York Introduction: Jörg Fuchs (Tübingen) |
| 09.20 – 11.30 | Session 6: Surgery Relevance of imaging and pre-treatment of HR neuroblastoma surgery Jörg Fuchs (Tübingen) Minimally invasive surgery for neuroblastoma: What’s new? Sabine Sarnacki (Paris) Surgery of ganglioneuroma Sabine Irtan (Paris) Complications associated with neuroblastoma surgery Andrew Davidoff (Memphis) Challenges in NB Surgery Chan Hon Chui (Singapur) The International Surgical Report Form and the complexity index for Neuroblastoma Patrizia Dall'Igna (Bari) The Methods of Local Control Quality Assessment after gross-total resection Jan Godzinski (Wroclaw) Chair: Sabine Sarnacki & Johannes Schulte |
| 11.30 – 11.50 | Coffee Break |
| 11.50 – 13.35 | Session 7: Clinical Trials GPOH results of Neuroblastoma studies Thorsten Simon (Köln) Neuroblastoma trials Asia Godfrey Chan (Hong Kong) High-risk neuroblastoma from the COG perspective Rochelle Bagatell (Philadelphia) SIOPEN approach to low- and intermediate risk neuroblastoma Maja Popovic-Beck (Lausanne) Therapeutic strategies for high-risk neuroblastoma in Europe Ruth Ladenstein (Wien) Management of infant Neuroblastoma Barbara Hero (Köln) Chair: Meredith Irwin & Jan Godzinski |
| 13.35 – 14.35 | Lunch Break |
| 14.35 – 15.45 | Session 8: Basic Research Evolving approaches to IL2-based therapeutics Steven Gillies (Boston) Downstream signalling pathways and ALK inhibitor resistance in neuroblastoma Johannes Schulte (Berlin) Cellular origin and genomic evolution of childhood neuroblastoma Dr. Frank Westermann (Heidelberg) Targeting SWI/SNF chromatin remodellers in neuroblastoma by SMARCA2/4 PROTAC-mediated degradation Chun-Sui Kwok (Liverpool) Free talks Chair: Barbara Hero & Peter Lang |
| 15.45 | Closing Remarks Peter Lang |
| 15.50 | Coffee |
